新城疫病毒样颗粒研究进展

doi:10.11843/j.issn.0366-6964.2014.05.002

摘要/Abstract

摘要：

病毒样颗粒（virus-like particles，VLPs）是指利用异源宿主系统表达的病毒结构蛋白自行组装成不含病毒基因组、不能复制、不具有感染能力的病毒样蛋白颗粒。VLPs具备构想逼真、安全、稳定、可刺激体液和细胞免疫应答、作为载体表达其他抗原以及可设计成区分自然感染与免疫接种等诸多优点。这些优点使得VLPs在过去30年中成为新一代疫苗制备平台。作者就新城疫VLPs相关研究进展进行较为详尽的综述，以期为中国新城疫VLPs的研究提供参考。

关键词: 新城疫病毒, 病毒样颗粒, 疫苗

Abstract:

Virus-like particles (VLPs) refers to the virus structural protein self assembling into particles without virus gneome by using heterologous host system.It can’t copy and does not have the infection ability.VLPs combine many of the advantages，such as，well-defined geometry，safety，high stability，inducing strong humoral and cellular immune responses，applicability as vectors for the presentation of foreign antigens and amenable to fulfil the Differentiating Infected from Vaccinated Animals (DIVA).On behalf of above advantages，over the last three decades，VLPs have evolved to become a widely accepted new technology in the field of vaccinology.Here，in order to provide reference to the research of Newcastle disease VLPs，we review the current status of Newcastle disease VLPs to provid a guidelines for us to study the Newcastle disease VLPs in the future.

Key words: Newcastle disease virus, virus-like particles, vaccine

中图分类号:

S852.659.5

戈胜强,赵明,吴晓东,王静静,刘华雷,包静月,王志亮. 新城疫病毒样颗粒研究进展[J]. 畜牧兽医学报, 2014, 45(5): 686-691.

GE Sheng-qiang， ZHAO Ming，WU Xiao-dong，WANG Jing-jing，LIU Hua-lei，BAO Jing-yue，WANG Zhi-liang. Progress of Newcastle Disease Virus-like Particles[J]. ACTA VETERINARIA ET ZOOTECHNICA SINICA, 2014, 45(5): 686-691.

参考文献

［1］PANDEY A，SINGH N，SAMBHARA S,et al.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses［J］.Hum Vaccin，2010，6(2):178-188.
［2］ZHOU S，LIU R，ZHAO X，et al.Viral proteomics：the emerging cutting-edge of virus research［J］. Sci China Life Sci，2011，54(6):502-512.
［3］FREUNDLICH M M.Origin of the Electron Microscope［J］.Science，1963，142(3589):185-188.
［4］PORTER K R，THOMPSON H P.A particulate body associated with epithelial cells cultured from mammary carcinomas of mice of a milk-factor strain［J］.J Eep Med，1948，88(1):15-24.
［5］戈胜强，王志亮.禽流感病毒样颗粒研究进展［J］.病毒学报，2013，29(2):224-232.
［6］KENDAL A P，GALPHIN J C，PALMER E L.Replication of influenza virus at elevated temperatures：production of virus-like particles with reduced matrix protein content［J］.Virology，1977，76(1):186-195.
［7］NEUMANN H，SCHWASS V，ECKERSKORN C，et al.Identification and characterization of the genes encoding three structural proteins of the Thermoproteus tenax virus TTV1［J］.Mol Gen Genet，1989，217(1):105-110.
［8］BURRELL C J，MACKAY P，GREENAWAY P J，et al.Expression in Escherichia coli of hepatitis B virus DNA sequences cloned in plasmid pBR322［J］.Nature，1979，279(5708):43-47.
［9］COHEN B J，RICHMOND J E.Electron microscopy of hepatitis B core antigen synthesized in E.coli［J］.Nature，1982，296(5858):677-679.
［10］SMITH G E，SUMMERS M D，FRASER M J.Production of human beta interferon in insect cells infected with a baculovirus expression vector［J］.Mol Cell Biol，1983，3(12):2156-2165.
［11］ZELTINS A.Construction and characterization of virus-like particles：a review［J］.Mol Biotechnol，2013，53(1):92-107.
［12］ROY P.Genetically engineered particulate virus-like structures and their use as vaccine delivery systems［J］.Intervirology，1996，39(1-2):62-71.
［13］GÓMEZ-PUERTAS P，ALBO C，PÉREZ-PASTRANA E，et al.Influenza virus matrix protein is the major driving force in virus budding［J］.J Virol，2000，74(24):11538-11547.
［14］LI T C，ZHANG J，SHINZAWA H，et al.Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus［J］.J Med Virol，2000，62(3):327-333.
［15］COURSAGET P.Serology for human papillomavirus［J］.Salud Publica Mex，2003，45(Sup3):S361-366.
［16］TAKAMURA S，NIIKURA M，LI T C，et al.DNA vaccine-encapsulated virus-like particles derived from an orally transmissible virus stimulate mucosal and systemic immune responses by oral administration［J］.Gene Ther，2004，11(7):628-635.
［17］CHACKERIAN B.Virus-like particles：flexible platforms for vaccine development［J］.Expert Rev Vaccines，2007，6(3):381-390.
［18］JENNINGS G T，BACHMANN M F.The coming of age of virus-like particle vaccines［J］.Biol Chem，2008，389(5):521-536.
［19］ROY P，NOAD R.Virus-like particles as a vaccine delivery system：myths and facts［J］.Hum Vaccin，2008，4(1):5-12.
［20］PLUMMER E M，MANCHESTER M.Viral nanoparticles and virus-like particles：platforms for contemporary vaccine design［J］.Wires Nanomed Nanobi，2010，3(2):174-196.
［21］ROLDÃO A，MELLADO M C，CASTILHO L R，et al.Virus-like particles in vaccine development［J］.Expert Rev Vaccin，2010，9(10):1149-1176.
［22］MICHEL M L，TIOLLAIS P.Hepatitis B vaccines：protective efficacy and therapeutic potential［J］.Pathol Biol (Paris)，2010，58(4):288-295.
［23］NOAD R，ROY P.Virus-like particles as immunogens［J］.Trends Microbiol，2003，11(9):438-444.
［24］FAUSCH S C，DA SILVA D M，EIBEN G L，et al.HPV protein/peptide vaccines：from animal models to clinical trials［J］. Front Biosci，2003，8:s81-91.
［25］STANLEY M A.Progress in prophylactic and therapeutic vaccines for human papillomavirus infection［J］.Expert Rev Vaccin，2003，2(3):381-389.
［26］HARPER D M，FRANCO E L，WHEELER C，et al.Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women：a randomised controlled trial［J］. Lancet，2004，364(9447):1757-1765.
［27］KEIM B.Controversy over cervical cancer vaccine spurs safety surveillance［J］.Nat Med，2007，13(4):392-393.
［28］CORONEL E C，MURTI K G，TAKIMOTO T，et al.Human parainfluenza virus type 1 matrix and nucleoprotein genes transiently expressed in mammalian cells induce the release of virus-like particles containing nucleocapsid-like structures［J］.J Virol，1999，73(8):7035-7038.
［29］CIANCANELLI M J，BASLER C F.Mutation of YMYL in the Nipah virus matrix protein abrogates budding and alters subcellular localization［J］.J Virol，2006，80(24):12070-12078.
［30］PATCH J R，CRAMERI G，WANG L F，et al.Quantitative analysis of Nipah virus proteins released as virus-like particles reveals central role for the matrix protein［J］.Virol J，2007，4:1.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781425/pdf/1743-422X-4-1.pdf.
［31］TAKIMOTO T，MURTI K G，BOUSSE T，et al.Role of matrix and fusion proteins in budding of Sendai virus［J］. J Virol，2001，75(23):11384-11391.
［32］SCHMITT A P，LESER G P，WANING D L，et al.Requirements for budding of paramyxovirus simian virus 5 virus-like particles［J］.J Virol，2002，76(8):3952-3964.
［33］LIU F，WU X，LI L，et al.Use of baculovirus expression system for generation of virus-like particles：successes and challenges［J］.Protein Expr Purif，2013，90(2)：104-116.
［34］KANG S M，SONG J M，QUAN F S，et al.Influenza vaccines based on virus-like particles［J］.Virus Res，2009，143(2):140-146.
［35］WANG X J，GU K，XIONG Q Y，et al.A novel virus-like particle based on hepatitis B core antigen and substrate-binding domain of bacterial molecular chaperone DnaK［J］.Vaccine，2009，27(52):7377-7384.
［36］JIANG Z，TONG G，CAI B，et al.Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris［J］.Protein Expr Purif，2011，80(2):203-210.
［37］MORRISON T G，PANTUA H D.Virus-like particles as vaccines for paramyxovirus：USA，WO2007019247 A2 ［P］.
［38］MAHMOOD K，SMITH G，PUSHKO P.Chimeric Newcastledisease virus VLPs：USA，WO 2008103819 A2 ［P］.
［39］PANTUA H D，MCGINNES L W，PEEPLES M E，et al.Requirements for the assembly and release of Newcastle disease virus-like particles［J］.J Virol，2006，80(22):11062-11073.
［40］MCGINNES L W，PANTUA H，LALIBERTE J P，et al.Assembly and biological and immunological properties of Newcastle disease virus-like particles［J］.J Virol，2010，84(9):4513-4523.
［41］冷勇，宋振辉，卿家超，等.猪传染性胃肠炎病毒M、sM基因重组杆状病毒的构建及病毒样颗粒的组装［J］.畜牧兽医学报，2013，44（9）：1432-1437.
［42］闻晓波.新城疫病毒样颗粒的构建及其出芽机制的研究［D］.北京：中国农业科学院，2006.
［43］吴芬芳，闫丽辉，曹殿军，等.新城疫病毒样颗粒(ND—VLPs)免疫效力的研究［J］.中国预防兽医学报，2008，30(1):42-46，63.
［44］MURAWSKI M R，MCGINNES L W，FINBERG R W，et al.Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice，with no evidence of immunopathology［J］.J Virol，2010，84(2):1110-1123.
［45］MCGINNES L W，GRAVEL K A，FINBERG R W，et al.Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins［J］.J Virol，2011，85(1):366-377.
［46］SHEN H，XUE C，LV L，et al.Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease［J］.Virus Res，2013，178(2):430-436.
［47］NAGY E，HUBER P，KRELL P J，et al.Synthesis of Newcastle disease virus (NDV)-like envelopes in insect cells infected with a recombinant baculovirus expressing the haemagglutinin-neuraminidase of NDV［J］.J Gen Virol，1991，72(Pt3):753-756.
［48］ONG H K，ALI A M，OMAR A R，et al.Cloning and expression of the HN， gene from the velogenic viscerotropic Newcastle disease virus strain AF2240 in Sf9 insect cells［J］.Cytotechnology，2000，32(3):243-251.
［49］李太元，金宁一，丁壮，等.新城疫病毒F₄₈E₈株HN基因在杆状病毒系统中表达［J］.中国生物制品学杂志，2002，15(6):334-336.
［50］SEAL B S，KING D J，SELLERS H S.The avian response to Newcastle disease virus［J］.Dev Comp Immunol，2000，24(2-3):257-268.
［51］TAKIMOTO T，PORTNER A.Molecular mechanism of paramyxovirus budding［J］.Virus Res，2004，106(2):133-145.
［52］SANDERSON C M，WU H H，NAYAK D P.Sendai virus M protein binds independently to either the F or the HN glycoprotein in vivo［J］.J Virol，1994，68(1):69-76.
［53］ALI A，NAYAK D P.Assembly of Sendai virus：M protein interacts with F and HN proteins and with the cytoplasmic tail and transmembrane domain of F protein［J］.Virology，2000，276(2):289-303.
［54］MORRISON T G.Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens［J］.Future Virol，2010，5(5):545-554.
［55］BRIGHT R A，CARTER D M，CREVAR C J，et al.Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle［J］.PLoS One，2008，3(1)：e1501.

[1]	武炜, 王飒, 孟春春, 仇旭升, 廖瑛, 谭磊, 宋翠萍, 刘炜玮, 孙英杰, 丁铲. 应用CRISPR/Cas9敲除HeLa细胞DDX21基因对新城疫病毒复制的影响[J]. 畜牧兽医学报, 2019, 50(7): 1433-1440.
[2]	武炜, 王飒, 孟春春, 仇旭升, 廖瑛, 谭磊, 宋翠萍, 刘炜玮, 孙英杰, 丁铲. 应用CRISPR/Cas9敲除HeLa细胞DDX21基因对新城疫病毒复制的影响[J]. 畜牧兽医学报, 2019, 50(7): 1433-1440.
[3]	胡焱, 段志强, 嵇辛勤, 赵佳福, 邓珊珊, 李世静, 熊建民. GST pull-down验证新城疫病毒基质蛋白与鸡importin β1蛋白的相互作用[J]. 畜牧兽医学报, 2019, 50(1): 126-133.
[4]	胡焱, 段志强, 嵇辛勤, 赵佳福, 邓珊珊, 李世静, 熊建民. GST pull-down验证新城疫病毒基质蛋白与鸡importin β1蛋白的相互作用[J]. 畜牧兽医学报, 2019, 50(1): 126-133.
[5]	徐兆坤, 李武, 王玉炯. 外泌体在机体抗结核分枝杆菌感染中的作用及其应用[J]. 畜牧兽医学报, 2018, 49(9): 1803-1809.
[6]	徐兆坤, 李武, 王玉炯. 外泌体在机体抗结核分枝杆菌感染中的作用及其应用[J]. 畜牧兽医学报, 2018, 49(9): 1803-1809.
[7]	魏润宇, 罗瑶瑶, 吕艳, 王静静, 郑东霞, 赵云玲, 刘文博, 刘华雷, 王志亮. 4株新出现的Ⅰ类新城疫病毒F基因的变异分析[J]. 畜牧兽医学报, 2018, 49(8): 1781-1788.
[8]	魏润宇, 罗瑶瑶, 吕艳, 王静静, 郑东霞, 赵云玲, 刘文博, 刘华雷, 王志亮. 4株新出现的Ⅰ类新城疫病毒F基因的变异分析[J]. 畜牧兽医学报, 2018, 49(8): 1781-1788.
[9]	万春和, 刘荣昌, 程龙飞, 傅光华, 施少华, 陈红梅, 傅秋玲, 黄瑜. 鸭肠炎病毒疫苗株EvaGreen实时荧光定量PCR方法的建立[J]. 畜牧兽医学报, 2018, 49(7): 1558-1566.
[10]	万春和, 刘荣昌, 程龙飞, 傅光华, 施少华, 陈红梅, 傅秋玲, 黄瑜. 鸭肠炎病毒疫苗株EvaGreen实时荧光定量PCR方法的建立[J]. 畜牧兽医学报, 2018, 49(7): 1558-1566.
[11]	段志强, 邓珊珊, 袁超, 高洪波, 嵇辛勤, 赵佳福, 阮涌. 新城疫病毒M蛋白核定位信号突变降低病毒的致病性[J]. 畜牧兽医学报, 2018, 49(12): 2690-2697.
[12]	段志强, 邓珊珊, 袁超, 高洪波, 嵇辛勤, 赵佳福, 阮涌. 新城疫病毒M蛋白核定位信号突变降低病毒的致病性[J]. 畜牧兽医学报, 2018, 49(12): 2690-2697.
[13]	梁圣, 赵新新, 程安春. 禽霍乱新型疫苗的研究进展[J]. 畜牧兽医学报, 2018, 49(11): 2317-2325.
[14]	谢军, 孙英杰, 周昌娈, 朱善元, 丁铲, 柏家林. 禽流感病毒H9N2与新城疫病毒在鸡成纤维细胞中共感染对病毒复制的影响[J]. 畜牧兽医学报, 2018, 49(11): 2521-2528.
[15]	梁圣, 赵新新, 程安春. 禽霍乱新型疫苗的研究进展[J]. 畜牧兽医学报, 2018, 49(11): 2317-2325.